Private Label Tranexamic Acid Vitamin C Gel Cleanser

The minimum order quantity for a private label tranexamic acid vitamin C gel cleanser typically ranges from 500 to 5,000 units depending on the manufacturing route you choose. For a stock or white-label formula — where the contract manufacturer already has a validated base containing TXA and a stable vitamin C derivative — MOQs of 500 to 1,000 units are realistic. These formulas are pre-tested for stability and safety, so the manufacturer can afford to run smaller batches. The trade-off is limited differentiation: you are choosing from existing formulations, and so are other brands that work with that same facility. Semi-custom routes, where you modify a stock base by adjusting active concentrations, swapping the fragrance, or changing the texture profile, generally carry MOQs in the 1,000–2,500 unit range. This is the sweet spot for most indie founders launching their first SKU. You get a formula that feels proprietary without the full cost of ground-up development. Fully custom development — where a cosmetic chemist creates the formula from scratch and you own the IP — typically starts at 2,500 units and more commonly requires 5,000 units or more before manufacturers can justify the R&D investment. Some specialty labs will do lower volumes for a significant upfront formulation fee ($3,000–$10,000+), essentially decoupling R&D cost from production cost. Several factors can push MOQs lower: choosing flexible contract manufacturers who specialize in indie brands, accepting generic stock packaging rather than custom-molded components, and launching in a single SKU size (e.g., 100 mL only) rather than multiple formats simultaneously. On the other hand, MOQs rise if you require specific certifications (COSMOS organic, Leaping Bunny cruelty-free, EWG Verified), use specialty actives that require minimum batch sizes from raw material suppliers, or need custom-molded packaging that has its own MOQ from the mold vendor. The most common mistake first-time founders make is assuming they can negotiate a 200-unit trial run and then scale. Most reputable GMP-certified facilities will not go below 500 units because the fixed costs of cleaning, line changeover, documentation, and QC do not scale proportionally below that threshold. If you genuinely need under 500 units for a market test, explore contract labs that offer small-batch formulation services rather than full production runs. AJ Cosmo Labs lists manufacturers across a range of MOQs; you can filter specifically for low-MOQ cosmetic partners inside the app to avoid wasting time briefing facilities that cannot serve your current volume.

The total cost to private label a tranexamic acid vitamin C gel cleanser has two components: development costs (one-time) and production costs (per unit, recurring). Development costs for a stock formula are near zero — the manufacturer has already paid for formulation and stability testing. For semi-custom work, expect $1,500–$4,000 for formulation adjustments, prototype iterations, and updated stability data. For a fully custom formula, development fees range from $5,000 to $15,000 or more, covering cosmetic chemist time, raw material sourcing, multiple prototype rounds, preservative efficacy testing (PET), stability testing at accelerated conditions (40°C/75% RH for 3 months minimum), and a safety assessment. Some manufacturers bundle these into the per-unit cost at higher volumes. Per-unit production cost for a finished, filled, and labeled gel cleanser at different volume tiers roughly breaks down as follows: at 500 units you might pay $5.50–$8.00 per unit; at 2,000 units, $3.80–$6.00; at 5,000 units, $2.50–$4.50. These ranges assume standard components (stock pump bottle, printed label) and a formula with TXA at 2–3% and a stable vitamin C derivative at 1–3%. Active ingredient cost is the biggest variable. Tranexamic acid (TXA) as a cosmetic-grade raw material costs approximately $80–$150 per kilogram. At a 2% inclusion rate in a 100 mL cleanser (which weighs roughly 100 g), TXA adds about $0.16–$0.30 per unit at small scale — significant but manageable. Vitamin C derivatives vary more widely: L-ascorbic acid is inexpensive ($20–$40/kg) but unstable in aqueous systems; ascorbyl glucoside runs $150–$300/kg; 3-O-ethyl ascorbic acid can exceed $500/kg. The derivative you choose materially affects unit economics. Packaging is frequently underestimated. A custom-printed airless pump bottle can cost $0.80–$2.50 per unit at low MOQ, versus $0.25–$0.50 for a stock opaque tube with an applied label. If your branding depends on premium packaging aesthetics, budget accordingly. Regulatory costs add another layer: safety assessment by a qualified toxicologist ($500–$2,000 depending on scope), stability testing if not included in manufacturer's fee ($500–$1,500), and FDA product listing (currently no fee, but requires time and accurate data). A realistic budget for a first launch at 1,000 units is $8,000–$18,000 all-in, covering development, production, packaging, safety documentation, and initial label printing. This does not include brand design, photography, or marketing spend.

The timeline from initial brief to finished goods for a private label tranexamic acid vitamin C gel cleanser depends heavily on which manufacturing route you choose and how prepared your brief is when you approach a manufacturer. For a stock formula with existing stability data, the fastest realistic timeline is 6–10 weeks. This breaks down roughly as: 1–2 weeks for quote review and contract execution; 1–2 weeks for packaging procurement (if using stock components from manufacturer's inventory); 2–4 weeks for production scheduling, batch manufacture, filling, and labeling; 1–2 weeks for QC release testing. This assumes your label artwork is finalized before the contract is signed — art delays are the single most common cause of timeline slippage at this stage. For a semi-custom modification, add 4–8 weeks for prototype development, one or two iteration rounds, and updated compatibility testing. Total timeline: 10–16 weeks. For a fully custom formula, the timeline is 16–28 weeks at minimum. Formulation development and prototyping take 6–10 weeks. Stability testing at accelerated conditions requires a minimum of 12 weeks (3 months at 40°C/75% RH) before a manufacturer will release a formula for commercial production. Safety assessment runs in parallel and typically takes 4–8 weeks depending on the toxicologist's workload. Production and QC release add another 4–6 weeks. Many founders underestimate the stability testing window — it cannot be compressed without compromising the data. Common delays that stretch every timeline: indecision on packaging components (especially if custom molds are involved — tooling alone takes 8–14 weeks), incomplete or changing formula briefs, label artwork revisions after the production slot is booked, and FDA facility registration issues on the manufacturer's side. If you are planning a seasonal launch — say, a Q4 holiday campaign — work backward from your desired in-stock date and add 4 weeks buffer. A semi-custom formula briefed in July may not be on shelves until November under an optimistic scenario, or January under a realistic one. Using AJ Cosmo Labs to post a detailed brief upfront — including target actives, MOQ, packaging preference, and regulatory requirements — shortens the negotiation and back-and-forth phase by getting qualified manufacturers to respond to a complete spec rather than spending weeks on discovery calls.

Tranexamic acid (TXA) is legal and widely used as a cosmetic ingredient in the United States. It is not classified as a drug by the FDA in topical cosmetic use, provided claims made about the product do not cross into drug territory — for example, claiming the product treats melasma, a medical condition, would invite FDA scrutiny and potential OTC drug classification. Transexamic acid is not on the FDA's list of prohibited or restricted cosmetic ingredients (21 CFR Part 700). It is also not restricted under California's Cleaning Product Right to Know Act or Prop 65 at the concentrations used in cosmetics (1–5%). In the EU, TXA is similarly not a restricted cosmetic substance under the EU Cosmetics Regulation (EC) No 1223/2009 Annex II or III, though EU brands must complete a Cosmetic Product Safety Report (CPSR) by a qualified safety assessor before placing the product on market. Safety profile: TXA is well-characterized pharmacologically (it is a lysine analogue used intravenously to prevent hemorrhage). At topical cosmetic concentrations, it has a strong safety record — it is non-irritating at 1–5%, non-comedogenic, and compatible with most surfactant systems used in cleansers. Patch testing and HRIPT (human repeated insult patch test) data are still recommended before launch as part of your safety substantiation file. Stability consideration: TXA is water-soluble and relatively stable across a wide pH range (4–8), which makes it well-suited for gel cleansers. However, it should be combined with antioxidants (like vitamin C derivatives) carefully, as some combinations can cause discoloration over time. Accelerated stability testing is non-negotiable — a formula that looks beautiful at batch release may discolor or develop off-odor at month three if not properly validated. The common mistake founders make is relying solely on a manufacturer's assurance that the formula is stable without requesting independent test data. Always ask for a stability report with real data points (appearance, pH, viscosity, active assay) at T=0, T=4 weeks (50°C), and T=12 weeks (40°C/75% RH) at minimum. MoCRA (2022) now requires safety substantiation to be on file for all cosmetic products sold in the US. Your safety file for a TXA vitamin C cleanser should include: raw material CoAs and safety data sheets, a formula-level safety assessment, PET results, stability data, and any clinical or consumer use data you have generated.

Choosing the right certified cosmetic contract manufacturer for a brightening gel cleanser with tranexamic acid and vitamin C protects your brand, speeds up retail onboarding, and reduces regulatory risk. Not all certifications are equally important, and the ones that matter most depend on your target sales channel. GMP certification (Good Manufacturing Practice) is the baseline. In cosmetics, the relevant standard is ISO 22716:2007, which specifies requirements for production, control, storage, and shipment of cosmetic products. A manufacturer without ISO 22716 or an equivalent documented GMP system is a significant risk — major retailers including Sephora, Ulta, and Target require GMP-compliant manufacturing. Ask for the certificate and its expiration date. Some US manufacturers operate under FDA's voluntary cosmetic GMP guidelines (21 CFR Part 700) rather than ISO 22716; both are acceptable but ISO 22716 is the international gold standard. FDA facility registration is now mandatory under MoCRA (2022) for domestic manufacturers and foreign manufacturers exporting to the US. Verify your manufacturer's registration number in the FDA's public database before signing a contract. Cruelty-free certification matters enormously in the brightening skincare category. Leaping Bunny (Cruelty Free International) is the most recognized standard globally; PETA's Beauty Without Bunnies program is widely recognized in the US. If your brand positioning targets conscious consumers, confirm the manufacturer does not test finished products or raw materials on animals, and that they can support your Leaping Bunny application with documentation. Clean beauty certifications like EWG Verified or Made Safe signal ingredient safety transparency and are increasingly required or preferred by retailers like Whole Foods Market and Target's clean beauty section. These require full formula disclosure to the certifying body and exclusion of flagged ingredients — confirm TXA and your chosen vitamin C derivative are on the acceptable lists for the certification you want. Vegan certification is separate from cruelty-free. Some vitamin C derivatives (ascorbyl palmitate, for example) are derived from plant sources, but beeswax or lanolin in an emollient system would disqualify a vegan claim. If vegan positioning is important, specify this in your brief. COSMOS organic (Europe) or USDA organic (US) certification is rarely applicable to a TXA cleanser because tranexamic acid is a synthetic ingredient and would prevent organic certification of the finished product. Don't invest in pursuing organic certification for this SKU. When using AJ Cosmo Labs, you can filter manufacturer listings by certification type, so you only engage facilities that already hold the credentials your brand and retail targets require. This saves weeks of qualification work.

Formula IP ownership is one of the most important — and most misunderstood — aspects of private label cosmetics, and the answer depends entirely on the contract you sign and the manufacturing route you choose. With a true stock or white-label formula, you do not own the formula. The manufacturer owns the formulation, and they may sell the same base to dozens of other brands. You own your brand name, your label design, and your packaging — but if you ever want to switch manufacturers, you start over from scratch with a new formula. This is the trade-off for low MOQs and fast timelines. With a fully custom formula developed specifically for your brand, IP ownership is negotiable — but not automatic. If the manufacturer's in-house cosmetic chemist develops the formula, the default ownership often sits with the manufacturer unless the contract explicitly assigns it to you. Before signing, insist on a clause that: (a) assigns full formula IP to your brand upon final payment, (b) requires the manufacturer to provide the complete formula — including exact raw material grades, suppliers, concentrations, and processing parameters — in a written document you retain. Without this documentation, "owning" the formula is meaningless because you cannot replicate it elsewhere. Some manufacturers charge a higher formulation fee in exchange for full IP transfer; others will not transfer IP at any price because the formula represents their core competitive advantage. This is a genuine deal-breaker point — if owning the formula is important to your long-term brand strategy, filter for manufacturers explicitly open to IP transfer before entering negotiations. For a semi-custom modification of a stock base, IP ownership is murkier. You typically own your modifications but not the underlying base. The practical implication: you may be able to replicate a similar formula elsewhere but not an identical one. Non-disclosure agreements (NDAs) should be signed before you share your formula brief or concept with any manufacturer. Most reputable contract manufacturers will sign a mutual NDA readily; hesitation is a red flag. One common mistake: founders assume that because they paid for development, they own the output. In the absence of a written IP assignment clause, courts in most jurisdictions default to the creator (the cosmetic chemist or the manufacturer) owning the work product. Get everything in writing, reviewed by an IP attorney if the formula is a meaningful competitive asset. AJ Cosmo Labs recommends clarifying IP terms in your initial brief when posting on the platform, so manufacturers who respond have already acknowledged your requirements before the first conversation.

Finding a vetted, low-MOQ contract manufacturer for a technically specific product like a tranexamic acid vitamin C gel cleanser requires more than a Google search or an Alibaba inquiry. The challenge is twofold: you need a facility with genuine experience formulating active-forward rinse-off products, and you need one willing to work at the volumes appropriate to an early-stage brand. The traditional approach — cold-emailing manufacturers found via trade directories like PCPC, Cosmetics Business, or NYSCC supplier lists — has a low hit rate for indie founders. Large contract manufacturers often have MOQ floors of 10,000+ units and focus on established brands. Smaller labs may lack GMP certification or stability testing infrastructure. Vetting takes months of calls, facility visits, and NDA negotiations before you receive a single quote. Trade shows like Cosmoprof North America, MakeUp in New York, and In-Cosmetics Global are productive venues because you can meet manufacturers face-to-face, assess their professionalism, and collect samples. However, these happen once or twice a year and require travel investment. Online B2B marketplaces for cosmetic contract manufacturing have improved significantly. The key differentiator between platforms is whether manufacturers are pre-vetted (confirming GMP certification, FDA registration, references) or self-listed without verification. Always confirm verification methodology before trusting a platform's supplier listings. AJ Cosmo Labs was built specifically to solve this problem for indie CPG founders. The iOS app pre-screens cosmetic manufacturers before listing them, so when you post a brief for a tranexamic acid vitamin C gel cleanser with a 1,000-unit MOQ ceiling, you receive responses only from facilities that can actually deliver at that scale. The brief-posting process prompts you to specify active concentrations, packaging preferences, certifications required, and timeline — giving manufacturers enough information to quote accurately rather than opening with a generic discovery call. When evaluating any manufacturer, request: ISO 22716 certificate (with expiration date), FDA facility registration number, a list of at least three active-forward rinse-off SKUs they have produced commercially, stability test data for a comparable formula, and a sample of their standard manufacturing agreement so you can review IP and liability terms before investing time in the relationship. Red flags to disqualify a supplier: unwillingness to sign an NDA before formula discussion, inability to provide CoAs for key raw materials, no documented PET protocol, and vague or shifting answers about their GMP status. Trust your instincts — a manufacturer that is evasive during the sales process will be worse during production.